Growth Opportunity Privately held oncology focused biotech with FDA breakthrough designation for non-invasive AM-EMF cancer therapy presents a unique, non-toxic platform ripe for strategic partnerships, co-development, or exclusive licensing deals to accelerate clinical expansion.

Clinical Expansion Anticipated IDE approvals to initiate HCC and GBM trials in H2 2025 signal near-term clinical collaboration opportunities with research organizations, contract research organizations, and academic medical centers for trial support, site partnerships, and data sharing.

Tech Synergy tech stack and device-centered platform offer collaboration potential with healthcare IT, cloud data integration, and medical device ecosystem players to enhance data capture, remote monitoring, and real-world evidence generation.

Revenue & Funding Current revenue range and $10M funding round indicate growing operations; potential for strategic investors or partnership deals that align funding with manufacturing scale, distribution, and regulatory milestones.

Market Positioning Targeting hepatocellular carcinoma and glioblastoma in solid tumors positions Autem Therapeutics as a niche innovator; opportunity to approach cancer care networks, payer discussions, and hospital systems seeking non-toxic, non-invasive treatment modalities.